Trial reportClinical and vaccine immunology : CVI2008
Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.
Trial report in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.Journal of acquired immune deficiency syndromes (1999) · 2012Trial
- AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.The Journal of infectious diseases · 2010Trial
- Past achievements and future perspectives of personalized vaccines and the role of dendritic cells.Immunologic research · 2026Review
- The urease E subunit vaccine stimulate the immune response versus Helicobacter pylori in animal model.Immunologic research · 2025Article
- Designing a Novel di-epitope Diphtheria Vaccine: A Rational Structural Immunoinformatics Approach.Current computer-aided drug design · 2025Article
- Article
- Article
- Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.Human vaccines & immunotherapeutics · 2016Article
- In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.Human vaccines & immunotherapeutics · 2015Article
- HIV DNA Vaccine: Stepwise Improvements Make a Difference.Vaccines · 2014Review
- Novel directions in HIV-1 vaccines revealed from clinical trials.Current opinion in HIV and AIDS · 2013Review
- Article
- Dendritic cell dysregulation during HIV-1 infection.Immunological reviews · 2013Review
- Synthetic DNA vaccine strategies against persistent viral infections.Expert review of vaccines · 2013Review
- Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Retrovirology · 2012Review
- Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Vaccine · 2010Article
- Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors.Biochemistry · 2010Article
- Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.Vaccine · 2010Article
- Article
- Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.Nature reviews. Immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A DNA vaccine encoding sequence-conserved human immunodeficiency virus type 1 (HIV-1)-derived cytotoxic T-lymphocyte (CTL) epitopes from multiple HIV-1 gene products (designated EP HIV-1090) was evaluated in a placebo-controlled, dose escalation phase 1 clinical trial of HIV-1-infected subjects receiving potent combination antiretroviral therapy. Patients received four intramuscular immunizations with EP HIV-1090 over a 4-month period at one of four doses (0.5, 1.0, 2.0, or 4.0 mg) or received a placebo. The vaccine was determined to be safe and well tolerated at all doses tested. CTL responses were measured from cryopreserved peripheral blood mononuclear cells using gamma interferon enzyme-linked immunospot assays, with and without in vitro peptide stimulation (IVS). Responses to one or more vaccine epitopes were detected throughout the course of vaccination in 37.5% (12/32) and 47% (15/32) of vaccine recipients measured without and with IVS, respectively, indicating possible vaccine-induced priming of epitope-specific T cells. However, differences in rates of response to HIV-1 epitopes between vaccine and placebo recipients did not achieve statistical significance. The HIV-1 epitope-specific CTL responses measured in the peripheral blood after vaccination were often low level and short-lived, and therefore, alternative immunization schedules, routes of delivery, or vaccine formulations may be required to increase vaccine potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.